Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma.

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	JOSTING A. MULLER H. BORCHMANN P. BAARS JW. METZNER B. DOHNER H. AURER I. ŠMARDOVÁ Lenka NIEDERWIESER D. SCHÄFER-ECKART K. SCHMITZ N. SUREDA A. GLOSSMAN J. DIEHL V. DE JONG D. HANSMANN M.L. RAEMAEKERS J. ENGERT A.
Year of publication	2010
Type	Article in Periodical
Magazine / Source	Journal of clinical oncology
MU Faculty or unit	Faculty of Medicine
Citation
Field	Oncology and hematology
Keywords	Hodgkin lymphoma
Description	High-dose chemotherapy (HDCT) followed by autologous stem-cell transplantation (PBSCT) has become the standard treatment for patients (pts) with relapsed Hodgkin's lymphoma (HL). The intensity of treatment needed is unclear. This European intergroup study evaluated the impact of sequential high-dose chemotherapy (SHDCT) before myeloablative therapy. PATIENTS:Pts with histologically confirmed, relapsed HL were treated with two cycles of DHAP. In the standard arm (A), pts received myeloablative therapy with BEAM followed by PBSCT. Pts in the experimental arm (B) also received sequential cyclophosphamide, methotrexate and etoposide in high-doses before BEAM. RESULTS:Mortality was similar in both arms (20% and 18%). With a median observation time of 42 mo., there was no significant difference in terms of FFTF (P = .56) and OS (P = .82) between arms. CONCLUSION:Compared with conventional HDCT, additional SHDCT is associated with more adverse effects and does not improve the prognosis of pts with relapsed HL.
Related projects:	Optimalizace diagnostiky a terapie maligních chorob a komplikací, které tyto maligní nemoci provázejí, s využitím nových molekulárně biologických metod.